Hong-mei Yi
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
CSNK1E sustains stemlike drug persistence in diffuse large B-cell lymphoma.
Journal: Blood
Published: August 08, 2025
CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell Lymphoma.
Journal: Blood
Published: August 08, 2025
A prognostic index integrating deep learning baseline PET/CT biomarkers and multi-omics profiling in diffuse large B cell lymphoma.
Journal: Cell reports. Medicine
Published: March 25, 2025
Clinicopathological characteristics, genetic aberrations, and optimized treatment strategies in double-hit and triple-hit lymphoma: a multi-center cohort study.
Journal: Molecular biomedicine
Published: January 21, 2025
Molecular heterogeneity of CD30+ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study.
Journal: EBioMedicine
Published: December 09, 2024
Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.
Journal: Clinical and translational medicine
Published: November 20, 2024
Practical microenvironment classification in diffuse large B cell lymphoma using digital pathology.
Journal: Cell reports. Medicine
Published: October 07, 2024
Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor.
Journal: Clinical and translational medicine
Published: February 26, 2024
KMT2D mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC/TGF-β1 axis.
Journal: International journal of biological sciences
Published: December 09, 2023
Last Updated: 09/26/2026